CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?

Zacks research recommends CorMedix (CRMD) as a "Strong Buy" over Mirum Pharmaceuticals (MIRM), citing CRMD's successful DefenCath launch, which generated $78.8 million in H1 2025 revenues and led to raised guidance, alongside its strategic $300 million acquisition of Melinta Therapeutics for diversification and projected 2025 sales and EPS increases of 411% and 607%. In contrast, MIRM, despite strong Livmarli sales of $161.4 million in H1 2025, faces significant revenue reliance on this single product and intensifying competition, resulting in a "Hold" rating. This analysis positions CRMD with a more compelling risk-reward profile due to its expanding portfolio and robust growth trajectory.

Analysis

A comparative analysis of specialized biotechs CorMedix (CRMD) and Mirum Pharmaceuticals (MIRM) reveals divergent risk-reward profiles despite both operating in high-growth niche markets. CorMedix demonstrates a robust growth trajectory following the successful commercial launch of its lead product, DefenCath, which generated $78.8 million in H1 2025 revenue and led to an upward revision of full-year guidance. The company has proactively mitigated single-product risk through its $300 million acquisition of Melinta Therapeutics, adding seven marketed therapies and diversifying its revenue stream. This strategy is reflected in exceptional analyst forecasts for 2025, which project 411% year-over-year sales growth and 607% EPS growth. In contrast, while Mirum Pharmaceuticals has posted impressive H1 2025 sales of $161.4 million for its lead drug, Livmarli (a 79.1% YoY increase), it remains heavily dependent on this single product for revenue. This concentration exposes MIRM to significant competitive pressure from Ipsen's Bylvay and potential regulatory setbacks. Although MIRM's own acquisitions have diversified its portfolio to some extent, its valuation is substantially richer, trading at a price-to-book ratio of 14.35 compared to CRMD's 3.47, suggesting a less favorable risk-adjusted outlook.

Key Decisions for Investors

• Given CorMedix's successful DefenCath launch, strategic diversification via the Melinta acquisition, and a more favorable valuation (P/B of 3.47), it presents a compelling growth case with a balanced risk profile.
• Investors in Mirum Pharmaceuticals should closely monitor the competitive landscape, particularly market share dynamics against Ipsen's Bylvay, as the company's high valuation and revenue concentration in Livmarli create significant risk despite strong sales growth.
• Consider that CRMD's projected 2025 EPS growth of 607% and diversified revenue base may offer a clearer path to profitability compared to MIRM, which is expected to narrow its losses by 61% but faces more direct competition.
• Key upcoming catalysts to watch are the Phase III data for CRMD's Rezzayo in H1 2026 and top-line data from MIRM's VISTAS study in Q2 2026, which could materially impact the outlook for both companies.